Business Wire

Samsung, Spin Digital and SES Showcase 8K Content via Satellite

Share

The SES annual Industry Days event kicks off today with the world leading satellite operator announcing that an 8K demo signal is broadcast directly to a flat screen TV with a built-in satellite receiver.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005829/en/

Samsung, Spin Digital and SES Showcase 8K Content via Satellite

Samsung, Spin Digital and SES Showcase 8K Content via Satellite

The 8K content broadcast via ASTRA 28.2 degrees East orbital slot is unveiled at the invite-only two-day event that is held in Luxembourg, with Spin Digital providing the expertise to encode high quality 8K signals, SES the bandwidth to broadcast the signal, and Samsung the 8K flat screen TV to receive and decode the broadcast signal directly.

The 8K content, with 7680x4320 pixels at 50 frames/s, is encoded by Spin Digital using its HEVC encoder at a bit rate of 70 Mbps for broadcast-grade quality, while the transmission is carried out by SES on a single 33 MHz transponder using DTH broadcast parameters. The 82” Samsung 8K Q950RB QLED production model TV receives this signal directly, and is using DVB-S2 transmission parameters specifically for this demo. This Samsung flagship TV features a 4000 Nits peak luminance, an 8K-compatible HEVC 50/60 fps video decoder, the latest HDMI interface and is capable of displaying High Dynamic Range (HDR) content. The TV will soon be available across Europe.

Transmitting broadcast-quality 8K content across multiple video formats calls for both efficient video coding and reliable infrastructure technology. While compression technology will become more efficient in the next few years, the demo underlines how satellite is already capable of reliably providing the transmission bitrates necessary to distribute 8K signals across continents.

Not only is the SES Industry Days an ideal platform to showcase the latest satellite-enabled products and services, the event has also gained the reputation of being a birthplace for innovation as over 300 attendees from 190 companies around the world gather together to discuss budding business concepts and how they can partner together to bring about more cost-efficient and effective solutions for their customers.

“Samsung is delighted to partner once again with SES with another leading edge technology demonstration at the SES Industry Days. Samsung is fully committed to the development of a future 8K TV market and this demonstration of the viability of the SES satellite platform is an important step towards that goal”, said John Adam, Head of Business Development and Industrial Affairs at Samsung Research UK.

“The collaboration with SES is helping to define the compression and quality settings for the new 8K format exploiting all the potential of the HEVC coding technology. Our next step is to enable similar quality and compression for live 8K HEVC,” said Mauricio Alvarez-Mesa, CEO of Spin Digital.

“Audiences today want richer video experiences that can be best fulfilled by immersive Ultra HD content, hence a lot of our broadcast and video customers are migrating their channels to high definition (HD) and Ultra HD. As their trusted partner, our vast TV audience reach and ability to deliver truly engaging video experiences via satellite mean we are well placed to differentiate their offerings and deliver customer success,” said Thomas Wrede, Vice-President of New Technology & Standards at SES Video. “It will be years before large 8K flat screens or video walls become a common sight in our living rooms. Nonetheless, we are anticipating the future by working with our industry partners to further improve the consumer’s video quality experience and to define an 8K satellite broadcasting standard.”

Follow us on:

Social Media
Blog
Media Library
White Papers

About SES

SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 351 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. The SES Video portfolio includes MX1, a leading media service provider offering a full suite of innovative services for both linear and digital distribution, and the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com

Contact information

Suzanne Ong
Public Relations
Tel. +352 710 725 500
suzanne.ong@ses.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CESTPress release

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti

Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CESTPress release

In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CESTPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CESTPress release

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The

Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con